ProductLife Group, winner of the best Buy&Build Strategy from Leaders League

Last week, Xavier Duburcq, CEO, and Thomas Galvain, Head of Corporate Development, received on behalf of ProductLife Group, the Award of the best Buy & Build Strategy from Leaders League. During the last round of the 23th Private Equity Exchange challenge, the jury recognized the value of PLG’s acquisition strategy and how it has supported the growth of the Group during the last 4 years, transforming it from a regional player into a global leader of 2,000 experts, supporting patient access to innovative, safe and effective medical solutions.
This comes as a recognition for the hard work of our teams as well as the loyalty of our clients in supporting such growth.

 

Follow our success story here

Biotech Excellence: Insights from Asebio's Last Report

Did you know that the biotech sector in Spain is booming? In 2023, AseBio – Asociación Española de Bioempresas published its latest report on the Spanish biotechnology sector. This comprehensive update highlights several significant developments.
At ProductLife Group, we congratulate AseBio – Asociación Española de Bioempresas on this comprehensive report and celebrate the growth of the biotech sector in Spain.

 

Learn how we can support your biotech

Successful Leader Panel on CMC at Bio-Europe

We were honored to host this conversation at EBD Group Bio-Europe Fall, on the topic of CMC development – an aspect that is often time overlooked but plays a crucial role in biotech asset valuation. A big thank you to our esteemed panelists: Johannes Roebers, PhD (ProductLife Group), Matthieu Coutet (Sofinnova Partners), Christoph Winterhalter (AGC Biologics), Corinne VENOT (BeiGene), Neil McLoughlin (NíoSync Limited) and our moderator Christelle Dagoneau (ProductLife Group) for their valuable contributions and insights on this topic.

Access the full recording here

Strategiqual, a ProductLife Group company is offering a new program of shared audits designed for pharmaceutical manufacturers and operators.

Many pharmaceutical companies work with the same service providers, so Strategiqual has developed this new service to help clients optimize costs by conducting audits in a shared manner. These audits will be carried out by a qualified senior consultant auditor from Strategiqual, offering benefits such as sharing resources, fostering collaboration, optimizing processes, ensuring compliance, and maintaining excellence. The first shared audit, focusing on the service provider HandiCaPZéro, will take place on February 10th and 11th, 2025, in Paris and Jaunay-Marigny.

 

Contact our experts here

Special AI Edition in Pharmaceutiques

We are excited to announce that the experts who wrote our last white paper titled “An Introduction to the Transformative Power of AI in Shaping the Pharmaceutical Industry” will be featured in the special AI edition of Pharmaceutiques this December.

Artificial intelligence is already revolutionizing key areas such as regulatory affairs, manufacturing, pharmacovigilance, and market access. In this report, we explore AI’s current impact and future potential in the pharmaceutical sector, alongside the challenges of data management, team adoption, and business model innovation.

 

Read our white paper here

Continuous Manufacturing in Pharmaceuticals: Critical Factors and Success Strategies Part 1

Continuous Manufacturing (CM) is revolutionizing how we produce drugs. With ICH Q13 providing a regulatory framework, companies can transition from batch manufacturing to a more efficient and flexible CM process. From boosting productivity to improving product quality, CM holds immense potential for new drugs, generics, and biosimilars. However, navigating regulatory frameworks like ICH Q13 can be challenging.

 

Dive deeper into the regulatory side of CM here

Continuous Manufacturing in Pharmaceuticals: Critical Factors and Success Strategies Part 2

What’s needed for successful regulatory submissions for Continuous Manufacturing? Transitioning from batch to Continuous Manufacturing in pharmaceuticals requires more than just advanced technology – it demands comprehensive knowledge, robust control strategies, and real-time monitoring tools like RTD and PAT.

In Part 2 of our expert interview with Jimmy Gandhi, our CM expert at ProductLife Group, we delve into the critical success factors that ensure regulatory approval during the transition from batch to CM.

Read more here about how to ensure compliance

Register to our news and events

Go to our Events to register
Go to our News to get insights

See all our news and events
November 2024 Monthly Newsletter